SURE-PD III
The Study of Urate Elevation in Parkinson's Disease, Phase 3 (SURE-PD3) was a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether utilizing oral inosine to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) could slow clinical decline in early PD. This study was conducted through the Parkinson's Study Group (PSG).
Read about the study design for SURE-PD3
Read about the study outcomes from SURE-PD3
Study Participants
SURE-PD3 enrolled 298 individuals with PD who did not yet require dopaminergic medication. This trial was concluded early due to lack of effect of the treatment on the primary outcome measure of disease progression.
Available Data
CLINICAL: performance, observational, and self-reported assessments of motor, cognitive, and functional staging
Request access to the de-identified raw dataset through the NINDS data archive
Request access to the PDBP-normalized dataset through the DMR
IMAGING: DaTscanTM neuroimaging
Contact the PSG Clinical Trials Coordination Center to request DaTscanTM imaging data
GENETIC: whole genome sequencing
Request access to the genetic data through AMP-PD
DNA from blood and plasma.
Serial plasma was collected at baseline, after 24hr on drug, and following drug washout.
Samples from the SURE-PD Phase 2 trial can also be requested through the BRAC.
Learn more about SURE-PD2